CVKD
$7.54
Market ClosedAs of Mar 17, 8:00 PM UTC
Cadrenal Therapeutics, Inc.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$7.54
Potential Upside
5%
Whystock Fair Value$7.92
Price
UndervaluedFair ValueOvervalued
Fundamentals
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart att...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-468.03%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.86
Recent News
Cadrenal Therapeutics, Inc.
CVKD: Acquires Factor XIa Inhibitors
Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors
Cadrenal will acquire eXIthera’s intravenous Factor XIa inhibitor frunexian, oral inhibitor EP-7327, and additional novel FXIa small molecules.
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...